	US 11,890,315 B2
	Stable ascorbic acid compositions and methods of using same
Dan Copeland, Chapel Hill, NC (US); and Carolyn Durham, Chapel Hill, NC (US)
Assigned to RENOVION, INC., Chapel Hill, NC (US)
Filed by RENOVION, INC., Chapel Hill, NC (US)
Filed on Oct. 7, 2022, as Appl. No. 17/938,861.
Application 17/938,861 is a continuation of application No. 16/764,781, granted, now 11,497,786, previously published as PCT/US2018/061686, filed on Nov. 16, 2018.
Claims priority of provisional application 62/684,700, filed on Jun. 13, 2018.
Claims priority of provisional application 62/588,300, filed on Nov. 17, 2017.
Prior Publication US 2023/0144527 A1, May 11, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/06 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61P 11/00 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/14 (2006.01); A61K 31/4418 (2006.01); A61K 31/47 (2006.01); A61K 45/06 (2006.01)

CPC A61K 38/063 (2013.01) [A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61P 11/00 (2018.01); A61K 9/0075 (2013.01); A61K 9/0078 (2013.01); A61K 9/08 (2013.01); A61K 9/14 (2013.01); A61K 31/4418 (2013.01); A61K 31/47 (2013.01); A61K 45/06 (2013.01)]

23 Claims

1. A method of treating a subject having a pulmonary or airway viral infection, comprising administering to the subject a therapeutically effective amount of a composition comprising:

(a) glutathione, a glutathione derivative, a glutathione conjugate, or a pharmaceutically-acceptable salt thereof;

(b) an ascorbic acid; and

wherein the molar ratio of (a):(b):(c) is about 0.1-0.5:0.5-1:1.